Skip to main content

Table 4 Survival analysis in different tumor types

From: Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia

Variables

OS (model 0)

 

OS (model 3)

 
 

Crude HR(95%CI)

Crude P

Adjusted HR(95%CI)

Adjusted P

Lung cancer

 CTI < 4.71

ref

 

ref

 

 CTI ≥ 4.71

1.51 (1.16–1.97)

0.002

1.22 (0.93–1.61)

0.151

Esophagus cancer

 CTI < 4.71

ref

 

ref

 

 CTI ≥ 4.71

2.64 (1.61–4.34)

 < 0.001

2.11 (1.05–4.21)

0.035

Gastric cancer

 CTI < 4.71

ref

 

ref

 

 CTI ≥ 4.71

1.70 (1.21–2.4)

0.002

1.28 (0.86–1.9)

0.221

Colorectal cancer

 CTI < 4.71

ref

 

ref

 

 CTI ≥ 4.71

3.24 (2.15–4.89)

 < 0.001

2.29 (1.42–3.71)

0.001

Female tumor

 CTI < 4.71

ref

 

ref

 

 CTI ≥ 4.71

3.02 (1.32–6.92)

0.009

1.51 (0.49–4.59)

0.472

Other cancer

 CTI < 4.71

ref

 

ref

 

 CTI ≥ 4.71

2.47 (1.63–3.73)

 < 0.001

1.82 (1.15–2.89)

0.011

  1. Model 0: Unadjusted
  2. Model 3: Adjusted for age, sex, BMI, tumor stage, KPS, surgery, chemotherapy, radiotherapy, smoking status, alcohol consumption, KPS, EORTC QLQ-C30, ECOG PS, PGSGA, diabetes, hypertension, coronary heart disease, and TSF
  3.  OS overall survival, HR hazards ratio, CI confidence interval, CTI CRP-TyG index, CRP C-reactive protein, TyG triglyceride-glucose index, BMI body mass index, KPS karnofsky performance status, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Core 30 (QLQ-C30), ECOG PS eastern cooperative oncology group performance status, PGSGA Patient Generated Subjective Global Assessment, TSF triceps skinfold thicknessÂ